The risk of candidiasis during treatment with bimekizumab for the management of plaque psoriasis: a 16-week multicentre real-world experience – IL PSO (Italian Landscape Psoriasis)

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Anti-interleukin 17 use has been associated with a higher risk of candidiasis, as this cytokine is involved in maintaining mucosal barriers and orchestrating immune responses to fungal pathogens. We performed a real-life retrospective multicentre study aiming to assess the risk of candidiasis in patients undergoing treatment with bimekizumab at labelled dosage for psoriasis, for at least 16 weeks.

Related collections

Most cited references 8

Record: found
Abstract: not found
Article: not found

Bimekizumab versus Secukinumab in Plaque Psoriasis

Kristian Reich, Richard Warren, Mark Lebwohl … (2021)

0 comments Cited 108 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: found

Is Open Access

Effectiveness and safety of bimekizumab for the treatment of plaque psoriasis: a real-life multicenter study—IL PSO (Italian landscape psoriasis)

Luigi Gargiulo, Alessandra Narcisi, Luciano Ibba … (2023)

Introduction Bimekizumab is a monoclonal antibody that targets Interleukin-17 A and F, approved for the treatment of moderate-to-severe plaque psoriasis. While bimekizumab has been evaluated in several phase-III clinical trials, real-world evidence is still very limited. Method This multicenter retrospective study included patients affected by plaque psoriasis treated with bimekizumab from May 1, 2022 to April 30, 2023, at 19 Italian referral hospitals. Patients affected by moderate-to-severe plaque psoriasis eligible for systemic treatments were included. The effectiveness of bimekizumab was evaluated in terms of reduction in psoriasis area and severity index (PASI) compared with baseline at weeks 4 and 16. The main outcomes were the percentages of patients achieving an improvement of at least 75% (PASI75), 90% (PASI90) and 100% (PASI100) in PASI score. Results The study included 237 patients who received at least one injection of bimekizumab. One hundred and seventy-one patients and 114 reached four and 16 weeks of follow-up, respectively. Complete skin clearance was achieved by 43.3% and 75.4% of patients at weeks 4 and 16, respectively. At week 16, 86.8% of patients reported no impact on their quality of life. At week 16, there were no significant differences between bio-naïve and bio-experienced patients in terms of PASI75, PASI90 and PASI100. The most commonly reported adverse events (AEs) were oral candidiasis (10.1%). No severe AEs or AEs leading to discontinuation were observed throughout the study. Conclusion Our experience supports the effectiveness and tolerability of bimekizumab in a real-world setting with similar results compared with phase-III clinical trials.

0 comments Cited 20 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: not found
Article: not found

Bimekizumab treatment in patients with moderate to severe plaque psoriasis: a drug safety evaluation

Angelo Ruggiero, Luca Potestio, Fabrizio Martora … (2023)

0 comments Cited 17 times – based on 0 reviews      Review now

Bookmark

All references

Author and article information

Journal

Title: Clinical and Experimental Dermatology

Publisher: Oxford University Press (OUP)

ISSN (Print): 0307-6938

ISSN (Electronic): 1365-2230

Publication date Created: October 07 2024

Publication date (Electronic): October 07 2024

Article

DOI: 10.1093/ced/llae400

SO-VID: 0630dab2-2c5b-4958-b998-fd5fa2b04e66

License:

https://academic.oup.com/pages/standard-publication-reuse-rights

History

Data availability:

Comments

Comment on this article

scite_

Smart Citations

Citing PublicationsSupportingMentioningContrasting

View Citations

See how this article has been cited at scite.ai

scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.